RenovoRx, Inc. (RNXT) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. RenovoRx, Inc. is a life sciences company developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared local drug-delivery device. The company is currently advancing its Phase III TIGeR-PaC clinical trial for a drug-device combination (IAG) while simultaneously scaling commercial sales of RenovoCath as a standalone device. As of May 7, 2026, the company had 45,099,133 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $563 | $197 |
| Gross Profit | $479 | $103 |
| Gross Margin | 85.1% | 52.3% |
| Net Loss | $(3,521) | $(2,420) |
| Net Loss Per Share | $(0.09) | $(0.08) |
| Cash and Cash Equivalents (End of Period) | $12,362 | $14,582 |
| Net Cash Used in Operating Activities | $(3,709) | $(3,381) |
| Net Cash Provided by Financing Activities | $9,047 | $10,811 |
Liquidity & Debt: The company reported no long-term debt. Total liabilities were $2.7 million, primarily consisting of a $701,000 common stock warrant liability and current operating liabilities. The company maintains a cash runway sufficient for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 186% year-over-year to $563,000, driven by the expansion of active commercial cancer centers from 8 (end of 2025) to 16 (as of May 6, 2026). This represents the company's strongest quarterly revenue performance to date.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 73% to $2.72 million due to headcount expansion for commercialization. Research and Development (R&D) expenses decreased 25% to $1.23 million, primarily due to reduced clinical trial costs for the TIGeR-PaC study.
- Financing Activity: In March 2026, the company closed a private placement raising approximately $10.0 million in gross proceeds, issuing 8.4 million shares of common stock, pre-funded warrants, and revenue milestone warrants.
- Warrant Liability: The fair value of the common stock warrant liability increased by $97,000, resulting in a non-cash loss, compared to a gain of $584,000 in the prior year.
Outlook, Guidance, and Risks
- Commercial Targets: Management targets 36 active commercial cancer centers by year-end 2026. The company expects up to 15 TIGeR-PaC trial sites to transition to commercial use in the second half of 2026.
- Clinical Trial Status: The Phase III TIGeR-PaC trial is 93% enrolled (106 of 114 patients randomized as of May 14, 2026). Enrollment closure is expected by the end of June 2026, with final data anticipated in mid-to-late 2027.
- Market Opportunity: The company estimates a $400 million peak annual U.S. sales opportunity for RenovoCath as a standalone device, with long-term potential in the billions as the platform expands.
- Key Risks:
- Nasdaq Compliance: The company is currently not in compliance with the Nasdaq minimum bid price requirement ($1.00 per share) and has 180 days to regain compliance or face potential delisting.
- Liquidity: While cash is sufficient for 12 months, the company expects to continue incurring losses and may require additional financing to fund operations and development.
- Regulatory: No drug-device combination products are currently approved for commercial sale; future success depends on FDA approval of IAG.
Investor Verification Checklist
- Revenue Sustainability: Verify the rate of repeat ordering from existing centers and the conversion rate of the 32 centers in the pipeline to active status.
- Nasdaq Compliance Plan: Confirm the specific strategy (e.g., reverse stock split) the company intends to use to regain compliance with the $1.00 minimum bid price requirement.
- Cash Burn Rate: Monitor the monthly cash burn rate to ensure the 12-month runway remains valid given the increased SG&A spend.
- Warrant Liability Impact: Assess the volatility of the warrant liability valuation and its potential impact on future net loss figures.
- Clinical Milestones: Track the June 2026 enrollment closure date for the TIGeR-PaC trial and the subsequent transition of trial sites to commercial revenue.